FDA Brief

Warning letters Food

FDA warning letter to

Moorish Science Temple, The Divine and National Movement of North America, Inc; #13 The Moorish American National Republic dba Moor Herbs, Inc.

High riskIssued Aug 1, 2023Posted Sep 19, 2023Division of Human and Animal Food Operations East VI

FDA warned Moor Herbs that its herbal products are unapproved drugs with disease claims and are made without required supplement quality controls.

What happened

FDA inspected the manufacturing facility from February 13, 2023 to March 16, 2023, and reviewed moorherbs.com in May 2023. FDA found website claims that products such as “Full Body Antibiotic,” “Anti-Viral,” and “Tumor Release” treat diseases including infections, HIV, and cancer, making them unapproved new drugs. The inspection also found dietary supplement manufacturing quality rule failures, including missing specifications, no quality control program, and missing or incomplete production records.

What FDA found

  1. FDA says the products are unapproved new drugs because the website claims they cure or treat diseases such as infections, HIV, and cancer without FDA approval.

    FD&C Act §§ 201(p), 301(d), 505(a) [21 U.S.C. 321(p), 331(d), 355(a)]
  2. FDA says the products are misbranded because they lack adequate directions for use for diseases that a layperson cannot safely self-treat.

    FD&C Act § 502(f)(1) [21 U.S.C. 352(f)(1)]
  3. FDA says the company did not set required specifications for the identity, purity, strength, and composition of components like Coltsfoot, Wild Cherry Bark, and Boneset Herb.

    21 CFR 111.70(b)(1)-(2)
  4. FDA says the company did not set labeling specifications or finished-product specifications for identity, purity, strength, composition, and contamination limits.

    21 CFR 111.70(d), 111.70(e)
  5. FDA says the company had no written quality control procedures or quality control program.

    21 CFR 111.103, 111.140(b)(1)
  6. FDA says the company lacked master manufacturing records and that batch production records were incomplete.

    21 CFR 111.205(a), 111.255(b), 111.260

What FDA wants

FDA asks the company to correct the violations described and to provide adequate evidence and supporting documentation for its corrective actions. The provided letter text does not include a response deadline.

Who should pay attention

  • consumers buying herbal disease treatments online
  • retailers or distributors selling Moor Herbs products
  • dietary supplement brands using similar website claims or lacking CGMP records

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk